Why Partner with us?

Aurore Life Sciences is a pure-play API and intermediates manufacturer with a robust product portfolio of 40+ commercially produced APIs across a wide range of therapeutic categories. We are completely Backward – Integrated in all our APIs ensuring a seamless manufacturing pipeline with no external constraints.

Our operations are backed by two state-of-the-art manufacturing sites with a combined capacity of 800 KL where one of which is USFDA approved and two Intermediate sites to support us.

Our dedicated R&D facility with over 120 experienced chemists enables us to conduct faster product development with a focus on cost reduction and developing competitive products.

Strict adherence and compliance to cGMP practices have secured us multiple regulatory approvals such as USFDA, EDQM, WHO Geneva, ANVISA, etc which enabled us to be a trusted vendor for leading pharmaceutical companies worldwide.

We foster exclusivity and continued trust from our valued clientele by maintaining a high level of confidentiality and trust in technology transfers and product development.


Our vision is to become the most preferred global leader in API manufacturing by pushing the boundaries of innovation, sustainability, and quality.


At Aurore Life Sciences, our mission is to manufacture high-quality APIs that meet the unique needs of our clients and exceed their expectations. We accomplish this by developing innovative and sustainable solutions and investing in the best talent, technology, and processes. Our focus on delivering exceptional customer service and support builds long-term relationships with our clients while making a positive impact on society and the environment. Our commitment to excellence, transparency, and accountability drives us to continually improve and grow as a company. Join us in our mission to create a better tomorrow through pharmaceutical excellence.

Our Journey till now

  • 2017
    Founded with the establishment
    of our R&D Facility
  • 2018
    Acquired an API facility (Previously
    Mylan (Viatris)) located at Jeedimetla
  • 2019
    Our Greenfield site (Phase 1 ) in
    Hyderabad was initiated
  • 2020
    Production at Phase I site (Kazhipally) with ~200KL Capacity kicked off with the construction of Phase II beginning
  • 2021
    Our largest facility with 400KL capacity
    (Kazhipally) was made fully operational.
  • 2021
    Received WHO Geneva Approval at
    Jeedimetla site for Nirmatrelvir

Our Values

  • Ingenuity

    We foster a culture of resourcefulness, creativity, and problem-solving to develop innovative solutions to identify new opportunities and approaches to API manufacturing.

  • Reliability

    We deliver on our promises and commitments to our customers and stakeholders And operate with integrity, accountability, and transparency to earn the trust and loyalty of our partners

  • Collaboration

    We promote open communication, active listening, and constructive feedback to foster a collaborative work environment and build strong relationships with our partners and clients by working together to achieve common goals and mutual benefits.

  • Agility

    We embrace change and adaptability in a rapidly evolving industry and global marketplace prioritizing speed and efficiency in all aspects of our operations, from R&D to manufacturing to delivery